Profound Medical Schedules First-Quarter 2026 Earnings Release
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Profound Medical ( (TSE:PRN) ) has issued an update.
Profound Medical Corp., a commercial-stage medical device maker, develops and markets AI-powered, MRI-guided, incision-free therapies such as its TULSA-PRO platform for personalized prostate treatment and its Sonalleve system for non-surgical management of bone metastases and gynecologic conditions.
The company’s technologies are approved in major markets including the United States, Europe, Canada, China, and the Middle East, positioning it as an innovator in interventional MRI procedures and minimally invasive oncology and gynecologic care.
On April 16, 2026, Profound Medical announced it will release its first quarter 2026 financial results after market close on Thursday, May 7, 2026, followed by a management-hosted conference call at 4:30 p.m. ET to review the results and discuss business developments.
The scheduled earnings release and call underscore the company’s ongoing efforts to update investors and other stakeholders on its financial performance and strategic progress in expanding adoption of its MRI-guided therapeutic platforms.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$12.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on PRN Stock
According to Spark, TipRanks’ AI Analyst, PRN is a Neutral.
The score is held down primarily by weak financial performance (large losses and significant cash burn) and bearish technicals (downtrend across key moving averages with negative momentum). The earnings call adds support via credible growth/profitability targets, reimbursement and pipeline tailwinds, while valuation remains constrained by ongoing losses and no stated dividend.
To see Spark’s full report on PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.
Its flagship TULSA-PRO platform supports personalized, minimally invasive prostate treatments, while its Sonalleve system targets bone metastases, desmoid tumors, osteoid osteoma, and gynecologic conditions, with regulatory approvals across major global markets.
The company leverages real-time MRI guidance to enhance clinical confidence, procedural control, and patient outcomes, and is also exploring additional applications such as non-invasive abdominal cancer ablation and hyperthermia-based cancer therapies.
Through these technologies, Profound aims to expand access to precise, personalized, and incision-free treatment options worldwide.
Average Trading Volume: 18,576
Technical Sentiment Signal: Sell
Current Market Cap: C$323M
Learn more about PRN stock on TipRanks’ Stock Analysis page.
